Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)P Chollet, P Schöffski, K Weigang-Köhler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1994
Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanomaC Cussac, E Mounetou, M Rapp, et al.
Oncology Research|March 25, 2006
Does survival increase in metastatic breast cancer with recently available anticancer drugs?C Abrial, M Leheurteur, A Cabrespine, et al.
Breast (Edinburgh, Scotland)|August 20, 2011
Late lines of treatment benefit survival in metastatic breast cancer in current practice?E Planchat, C Abrial, E Thivat, et al.
Cancer|June 22, 1999
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer ChronotherapyF Lévi, R Zidani, S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1997
Clinical and pathological response to primary chemotherapy in operable breast cancerP Chollet, S Charrier, E Brain, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancersC Abrial, M A Mouret-Reynier, S Amat, et al.
Cancer Investigation|October 21, 2011
Prognostic value of initial tumor parameters after metastatic relapseE Planchat, X Durando, C Abrial, et al.
Oncology|November 7, 2012
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errorsE Thivat, I Van Praagh, A Belliere, et al.
Melanoma Research|February 8, 2000
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies GroupH Cure, P Souteyrand, R Ouabdesselam, et al.
Pageof 18